Regulation of renal 12(S)-hydroxyeicosatetraenoic acid in diabetes by angiotensin AT1 and AT2 receptors.
Diabetes is associated with increased production of 12(S)-hydroxyeicosatetraenoic acid [12(S)-HETE]. The mechanisms involved in this process remain unclear. We hypothesized that hyperglycemia and angiotensin II (ANG II) regulate renal 12(S)-HETE production via a balance between angiotensin AT(1) and AT(2) receptors activities. Using a microdialysis technique, renal interstitial fluid (RIF) levels of ANG II and 12(S)-HETE were monitored in normal control and streptozotocin-induced diabetic rats at baseline and then weekly thereafter for 12 wk. In a second group of normal and diabetic rats, 3 wk after development of diabetes, we monitored RIF 12(S)-HETE levels in response to acute AT(1) receptor blockade with valsartan or AT(2) receptor blockade with PD123319 individually or combined. Two weeks after induction of diabetes there was a 404% increase in ANG II (P < 0.05), a 149% increase in 12S-HETE (P < 0.05), and a 649% increase in urinary albumin excretion (P < 0.05). These levels remained elevated throughout the study. PD123319 given alone had no effect on 12(S)-HETE. Valsartan decreased 12(S)-HETE by 61.6% (P < 0.0001), a response that was abrogated when PD123319 was given with valsartan. These data demonstrate that hyperglycemia increases renal ANG II and 12(S)-HETE levels. The increase in 12(S)-HETE is mediated via AT(1) receptor. The attenuation of the effects of AT(1) receptor blockade by PD123319 suggests that AT(2) receptor contributes to the downregulation of renal 12(S)-HETE production.
Abdel-Rahman
Emaad M
EM
Department of Medicine, University of Virginia School of Medicine, Charlottesville, Virginia 22908-1409, USA.
Abadir
Peter M
PM
Siragy
Helmy M
HM
D019377:12-Hydroxy-5,8,10,14-eicosatetraenoic Acid / Q000378:metabolism*; D000804:Angiotensin II / Q000378:metabolism; D047228:Angiotensin II Type 1 Receptor Blockers / Q000494:pharmacology; D057912:Angiotensin II Type 2 Receptor Blockers; D000818:Animals; D001786:Blood Glucose / Q000378:metabolism; D001794:Blood Pressure / Q000187:drug effects; D001835:Body Weight / Q000187:drug effects; D003921:Diabetes Mellitus, Experimental / Q000378:metabolism*; D003928:Diabetic Nephropathies / Q000378:metabolism*; D007004:Hypoglycemic Agents / Q000494:pharmacology; D007093:Imidazoles / Q000494:pharmacology; D066298:In Vitro Techniques; D007328:Insulin / Q000494:pharmacology; D007668:Kidney / Q000378:metabolism*; D008297:Male; D017551:Microdialysis; D011725:Pyridines / Q000494:pharmacology; D051381:Rats; D017207:Rats, Sprague-Dawley; D044140:Receptor, Angiotensin, Type 1 / Q000378:metabolism*; D044139:Receptor, Angiotensin, Type 2 / Q000378:metabolism*; D013777:Tetrazoles / Q000494:pharmacology; D014633:Valine / Q000031:analogs & derivatives / Q000494:pharmacology; D000068756:Valsartan
D047228:Angiotensin II Type 1 Receptor Blockers; D057912:Angiotensin II Type 2 Receptor Blockers; D001786:Blood Glucose; D007004:Hypoglycemic Agents; D007093:Imidazoles; D007328:Insulin; D011725:Pyridines; D044140:Receptor, Angiotensin, Type 1; D044139:Receptor, Angiotensin, Type 2; D013777:Tetrazoles; D000804:Angiotensin II; C073402:PD 123319; D019377:12-Hydroxy-5,8,10,14-eicosatetraenoic Acid; D000068756:Valsartan; D014633:Valine
Diabetologia. 2002 Jan;45(1):125-33
11845232
Am J Physiol Renal Physiol. 2002 Nov;283(5):F985-94
12372774
Curr Opin Nephrol Hypertens. 1997 Mar;6(2):111-8
9146971
J Am Soc Nephrol. 2008 Mar;19(3):559-69
18235084
Hypertension. 2005 Jan;45(1):133-7
15534073
J Cell Physiol. 1996 Nov;169(2):391-400
8908207
Prostaglandins Other Lipid Mediat. 1998 Jan;55(1):3-25
9661215
Endocrinology. 2003 Jun;144(6):2229-33
12746279
Metabolism. 1998 Mar;47(3):257-63
9500559
Am J Physiol Regul Integr Comp Physiol. 2007 Oct;293(4):R1461-7
17670863
Nephrol Dial Transplant. 1998 May;13(5):1131-42
9623541
J Clin Invest. 1988 Dec;82(6):2136-41
3143746
Kidney Int. 2001 Apr;59(4):1354-62
11260396
J Clin Invest. 1997 Jul 15;100(2):264-9
9218502
Kidney Int. 2003 Oct;64(4):1208-13
12969138
Hypertension. 1995 May;25(5):1021-4
7737709
Am J Kidney Dis. 2008 Jan;51(1 Suppl 1):S1-320
18086389
Am J Physiol Renal Physiol. 2001 Feb;280(2):F254-65
11208601
J Clin Invest. 1987 Dec;80(6):1763-9
2824567
Kidney Int. 2006 Feb;69(3):512-9
16514433
Hypertension. 1994 Jan;23(1 Suppl):I142-7
8282345
Diabetologia. 1996 Mar;39(3):275-80
8721772
Clin Exp Pharmacol Physiol. 1992 May;19(5):343-7
1325883
J Hypertens. 2004 Aug;22(8):1571-7
15257181
Clin Exp Pharmacol Physiol. 2002 Jan-Feb;29(1-2):127-31
11906471
Semin Nephrol. 2004 Mar;24(2):93-100
15017521
Am J Physiol. 1993 Oct;265(4 Pt 2):F477-86
8238377
N Engl J Med. 2001 Sep 20;345(12):851-60
11565517
Am J Physiol. 1991 Aug;261(2 Pt 2):H451-6
1908641
Kidney Int. 1998 Mar;53(3):540-7
9507197
Am J Physiol. 1992 Sep;263(3 Pt 2):F436-42
1415572
Hypertension. 2000 May;35(5):1074-7
10818067
Diabetes. 1999 Nov;48(11):2229-39
10535459
N Engl J Med. 2001 Sep 20;345(12):870-8
11565519
J Clin Invest. 1999 Jun;103(11):1597-604
10359569
J Clin Invest. 1996 Apr 15;97(8):1978-82
8621783
J Hypertens. 2002 Aug;20(8):1615-24
12172324
N Engl J Med. 2001 Sep 20;345(12):861-9
11565518
J Clin Endocrinol Metab. 1996 May;81(5):1940-5
8626861
Biochem Biophys Res Commun. 1983 Apr 15;112(1):242-9
6838610
J Lipid Res. 2003 Dec;44(12):2391-9
12951362
Hypertension. 2002 Jan;39(1):129-34
11799091
J Am Soc Nephrol. 2005 Feb;16(2):352-62
15615821
Am J Physiol. 1990 Dec;259(6 Pt 2):H1774-80
2124426
Diabetes. 1996 Apr;45(4):522-30
8603776
J Am Soc Nephrol. 1999 Feb;10(2):245-55
10215323
J Clin Invest. 1993 Sep;92(3):1366-72
7690779
Blood. 2000 Apr 1;95(7):2304-11
10733500
Endocrine. 2002 Aug;18(3):295-301
12450322
J Clin Invest. 1985 Feb;75(2):404-12
3156147
J Clin Invest. 1994 Feb;93(2):536-42
8113392
Proc Natl Acad Sci U S A. 1993 Jun 1;90(11):4947-51
8506339